Biohaven: Opakalim Seizure Control and Biomarker Wins
Biohaven's Opakalim Seizure Control and Biomarker Wins
Biohaven reported prolonged seizure control with opakalim and deep biomarker reductions with BHV-1300 and BHV-1400 ahead of mid-2026 pivotal starts.
Opakalim Seizure Control
Opakalim 75 mg once-daily tripled median time to second generalized tonic-clonic seizure (141 days vs. 47 days placebo). In focal epilepsy open-label extension, 54% of patients achieved ≥50% seizure reduction over six months.
Safety Profile
Opakalim was well tolerated across studies (1,000+ subjects) with low CNS adverse event rates (no somnolence, dizziness, fatigue, or memory impairment).
BHV-1300 and BHV-1400 Biomarker Wins
BHV-1300 (MoDE) reduced pathogenic TSHR-IgG1 >80% by week 12 and normalized T4 and T3 in Graves' patients. BHV-1400 (TRAP) cut Gd-IgA1 >60% within 48 hours and ~70% by one month, with early eGFR, UPCR, and hematuria improvements. Both programs are set to start Phase 3 in mid-2026.
Impacted Symbols
Symbols affected by this headline and their sentiment signals
The news, analyses, and comments on this platform do not constitute investment advice. When making investment decisions, you should conduct your own research and consult with a qualified financial advisor if necessary. FiNews cannot be held responsible for any losses that may arise from the use of this information.